Renaissance Technologies's VRTX Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 505,048 shares of Vertex Pharmaceuticals Incorporated (VRTX) worth $228.97 M, representing 0.36% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in VRTX, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2017, adding 1.48 M shares. Largest reduction occurred in Q4 2020, reducing 1.63 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Vertex Pharmaceuticals Incorporated (VRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vertex Pharmaceuticals Incorporated (VRTX) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -230,840 | Reduce 31.37% | 505,048 | $453.36 |
| Q3 2025 | -269,000 | Reduce 26.77% | 735,888 | $391.64 |
| Q2 2025 | -166,683 | Reduce 14.23% | 1 M | $445.20 |
| Q1 2025 | -225,638 | Reduce 16.15% | 1.17 M | $484.82 |
| Q4 2024 | -234,284 | Reduce 14.36% | 1.4 M | $402.70 |
| Q3 2024 | +65,105 | Add 4.16% | 1.63 M | $465.08 |
| Q2 2024 | -14,100 | Reduce 0.89% | 1.57 M | $468.72 |
| Q1 2024 | -11,200 | Reduce 0.70% | 1.58 M | $418.01 |
| Q4 2023 | -72,400 | Reduce 4.35% | 1.59 M | $406.89 |
| Q3 2023 | +391,927 | Add 30.81% | 1.66 M | $347.74 |
| Q2 2023 | -125,574 | Reduce 8.98% | 1.27 M | $0.35 |
| Q1 2023 | -849,017 | Reduce 37.79% | 1.4 M | $0.32 |
| Q4 2022 | +107,867 | Add 5.04% | 2.25 M | $0.29 |
| Q3 2022 | +377,717 | Add 21.45% | 2.14 M | $289.54 |
| Q2 2022 | +53,800 | Add 3.15% | 1.76 M | $281.79 |
| Q1 2022 | +80,500 | Add 4.95% | 1.71 M | $260.97 |
| Q4 2021 | -264,618 | Reduce 13.99% | 1.63 M | $219.60 |
| Q3 2021 | -385,798 | Reduce 16.94% | 1.89 M | $181.39 |
| Q2 2021 | -123,000 | Reduce 5.12% | 2.28 M | $201.63 |
| Q1 2021 | -1.18 M | Reduce 32.88% | 2.4 M | $214.89 |
| Q4 2020 | -1.63 M | Reduce 31.32% | 3.58 M | $236.34 |
| Q3 2020 | -574,400 | Reduce 9.94% | 5.21 M | $272.12 |
| Q2 2020 | -1.08 M | Reduce 15.72% | 5.78 M | $290.31 |
| Q1 2020 | -216,900 | Reduce 3.07% | 6.86 M | $237.95 |
| Q4 2019 | +1.28 M | Add 22.03% | 7.08 M | $218.95 |
| Q3 2019 | +243,300 | Add 4.38% | 5.8 M | $169.42 |
| Q2 2019 | +477,100 | Add 9.39% | 5.56 M | $183.38 |
| Q1 2019 | +744,417 | Add 17.18% | 5.08 M | $183.95 |
| Q4 2018 | +245,183 | Add 6.00% | 4.33 M | $165.71 |
| Q3 2018 | +38,500 | Add 0.95% | 4.09 M | $192.74 |
| Q2 2018 | +1.2 M | Add 42.08% | 4.05 M | $169.96 |
| Q1 2018 | +3,000 | Add 0.11% | 2.85 M | $162.98 |
| Q4 2017 | +1.48 M | Add 108.18% | 2.85 M | $149.86 |
| Q3 2017 | +1.35 M | Add 6204.24% | 1.37 M | $152.04 |
| Q2 2017 | -18,417 | Reduce 45.91% | 21,700 | $128.85 |
| Q1 2017 | +40,117 | New Buy | 40,117 | $109.36 |
| Q3 2016 | -60,517 | Sold Out | 0 | $0.00 |
| Q2 2016 | -52,100 | Reduce 46.26% | 60,517 | $86.03 |
| Q1 2016 | +51,300 | Add 83.66% | 112,617 | $79.49 |
| Q4 2015 | +61,317 | New Buy | 61,317 | $125.84 |
| Q2 2015 | -159,317 | Sold Out | 0 | $0.00 |
| Q1 2015 | +159,317 | New Buy | 159,317 | $117.97 |
| Q2 2014 | -312,164 | Sold Out | 0 | $0.00 |
| Q1 2014 | +312,164 | New Buy | 312,164 | $70.72 |
| Q4 2013 | -139,220 | Sold Out | 0 | $0.00 |
| Q3 2013 | +139,220 | New Buy | 139,220 | $75.82 |
Renaissance Technologies's Vertex Pharmaceuticals Incorporated Investment FAQs
Renaissance Technologies first purchased Vertex Pharmaceuticals Incorporated (VRTX) in Q3 2013, acquiring 139,220 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Vertex Pharmaceuticals Incorporated (VRTX) for 46 quarters since Q3 2013.
Renaissance Technologies's largest addition to Vertex Pharmaceuticals Incorporated (VRTX) was in Q4 2017, adding 2,847,917 shares worth $426.79 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 505,048 shares of Vertex Pharmaceuticals Incorporated (VRTX), valued at approximately $228.97 M.
As of the Q4 2025 filing, Vertex Pharmaceuticals Incorporated (VRTX) represents approximately 0.36% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Vertex Pharmaceuticals Incorporated (VRTX) was 7,076,582 shares, as reported at the end of Q4 2019.